ストックスクリーナーアプリを入手
3.52
4.88%
-0.17
前日終値:
$3.69
開ける：
$3.61
24時間の取引高:
3.79M
Relative Volume:
1.00
時価総額：
$1.28B
収益：
$3.06M
当期純損益:
$-141.62M
株価収益率:
-4.7872
EPS:
-0.7353
ネットキャッシュフロー:
$-78.67M
1週間 パフォーマンス:
-5.90%
1か月 パフォーマンス:
+2.93%
6か月 パフォーマンス:
-23.19%
1年 パフォーマンス:
+118.01%
1日の値動き範囲:
$3.45
$3.6399
1週間の範囲:
$3.45
$3.79
52週間の値動き範囲:
$1.15
$6.75
Ataibeckley Inc Stock (ATAI) Company Profile
名前
Ataibeckley Inc
セクター
電話
49 89 2153 9035
住所
PROF. J.H. BAVINCKLAAN 7, AMSTELVEEN
Compare ATAI vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ATAI
Ataibeckley Inc
|
3.5174 | 1.34B | 3.06M | -141.62M | -78.67M | -0.7353 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.11 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
762.60 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
724.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.86 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
291.33 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ataibeckley Inc Stock (ATAI) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-20 | 開始されました | Guggenheim | Buy |
| 2025-10-13 | 開始されました | Needham | Buy |
| 2025-07-29 | 開始されました | Oppenheimer | Outperform |
| 2024-11-18 | 繰り返されました | H.C. Wainwright | Buy |
| 2024-04-03 | アップグレード | Maxim Group | Hold → Buy |
| 2022-11-01 | 開始されました | Loop Capital | Buy |
| 2021-11-30 | 開始されました | Maxim Group | Buy |
| 2021-11-11 | 開始されました | ROTH Capital | Buy |
| 2021-10-18 | 開始されました | H.C. Wainwright | Buy |
| 2021-09-01 | 開始されました | Jefferies | Buy |
| 2021-07-13 | 開始されました | Berenberg | Buy |
| 2021-07-13 | 開始されました | Canaccord Genuity | Buy |
| 2021-07-13 | 開始されました | Cantor Fitzgerald | Buy |
| 2021-07-13 | 開始されました | Citigroup | Buy |
| 2021-07-13 | 開始されました | Cowen | Outperform |
| 2021-07-13 | 開始されました | Credit Suisse | Outperform |
| 2021-07-13 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2021-07-08 | 開始されました | Aegis Capital | Buy |
すべてを表示
Ataibeckley Inc (ATAI) 最新ニュース
Is It Time To Reassess AtaiBeckley (ATAI) After Its Recent Share Price Swings? - simplywall.st
Price to sales ratio of AtaiBeckley Inc. – XETR:B72 - TradingView
AtaiBeckley Inc (ATAI)’s Drug Candidate EMP-01 Shows Positive Results in Key Study - Yahoo Finance
ATAI SEC FilingsAtai Beckley Inc 10-K, 10-Q, 8-K Forms - Stock Titan
AtaiBeckley (FRA:B72) PB Ratio : 5.65 (As of Mar. 04, 2026) - GuruFocus
AtaiBeckley (ATAI) to Initiate Phase 3 Depression Study Following Positive FDA Meeting - Insider Monkey
AtaiBeckley Inc (ATAI)'s Drug Candidate EMP-01 Shows Positive Results in Key Study - Finviz
Weighing AtaiBeckley (ATAI) Valuation After Strong One Year Return And Recent Share Price Weakness - Yahoo Finance
AtaiBeckley says aligned with FDA on dual-trial design Phase 3 BPL-003 program - TipRanks
AtaiBeckley's BPL-003: Is It a Breakthrough for BTD or a Risky Investment? - Bitget
AtaiBeckley (FRA:B72) Cyclically Adjusted PS Ratio : (As of Mar. 04, 2026) - GuruFocus
AtaiBeckley (FRA:B72) Shiller PE Ratio : (As of Mar. 03, 2026) - GuruFocus
AtaiBeckley (FRA:B72) Cyclically Adjusted Price-to-FCF : (As of Mar. 03, 2026) - GuruFocus
Why AtaiBeckley (ATAI) Is Down 7.3% After FDA Backs BPL-003 Phase 3 Depression Trials - simplywall.st
ATAI Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
AtaiBeckley Inc. Share PriceATAI, RNS News, Articles, Quotes, & Charts (NASDAQ:ATAI) - Proactive Investors
AtaiBeckley reports encouraging Phase 2a data for EMP-01 in social anxiety - Proactive financial news
Berenberg Adjusts AtaiBeckley Price Target to $13 From $12, Maintains Buy Rating - marketscreener.com
AtaiBeckley to Advance BPL-003 Depression Therapy to Late-Stage Program Following US FDA Meeting - marketscreener.com
AtaiBeckley Announces Successful End-of-Phase 2 Meeting for BPL-003 in Treatment-Resistant Depression - Investing News Network
AtaiBeckley cleared for Phase 3 trials of nasal spray depression treatment after FDA backing - Proactive financial news
AtaiBeckley receives FDA support for depression drug trials - Investing.com
Ataibeckley announces successful end-of-phase 2 meeting for BPL-003 in treatment-resistant depression - marketscreener.com
AtaiBeckley receives FDA support for depression drug trials By Investing.com - Investing.com UK
ATAI Stock Receives Buy Rating with Increased Price Target Today - GuruFocus
Analysts Are Bullish on These Healthcare Stocks: Nuvalent (NUVL), Atai Beckley N.V. (ATAI) - The Globe and Mail
AtaiBeckley Inc. (ATAI) Discusses Positive Topline Results From Exploratory Phase IIa Study of EMP-01 in Social Anxiety DisorderSlideshow (NASDAQ:ATAI) 2026-02-28 - Seeking Alpha
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
AtaiBeckley’s MDMA-based drug for anxiety shows benefit in Phase IIa trial - Yahoo
TD Cowen Conference: ATAI, BCRX, BMRN And More To Present Key Updates - RTTNews
AtaiBeckley Inc. (ATAI): Unpacking The 233.90% Potential Upside In The Biotech Sector - DirectorsTalk Interviews
Psychedelic: AtaiBeckley reports EMP-01 met primary objective in Phase 2a trial - TipRanks
AtaiBeckley reports positive Phase 2a trial results for EMP-01 By Investing.com - Investing.com Canada
[144] Atai Beckley N.V. SEC Filing - Stock Titan
AtaiBeckley Announces Positive Topline Results from an Exploratory Phase 2a Trial of EMP-01 in Social Anxiety Disorder - Investing News Network
Small cap wrap: Northstar Gold, AtaiBeckley, Alvopetro Energy, C3 Metals… - Proactive Investors
R-MDMA phase II cheers up Ataibeckley in SAD - BioWorld MedTech
AtaiBeckley stock drops on Phase 2a data; Disc to refile rare disease drug - Endpoints News
Analysts Offer Insights on Healthcare Companies: CareDx (CDNA) and Atai Beckley N.V. (ATAI) - The Globe and Mail
AtaiBeckley reports positive results from Phase 2a social anxiety disorder trial - Proactive Investors
AtaiBeckley's Phase 2a Study Of EMP 01 In Social Anxiety Disorder Meets Key Goal - Nasdaq
AtaiBeckley Announces Positive Topline Results from an Exploratory Phase 2a Trial of EMP-01 (oral R-MDMA) in Social Anxiety Disorder - Bitget
AtaiBeckley Shares Rise 2% on Positive Mid-Stage Trial Results - Investing.com India
AtaiBeckley Shares Rise 2% on Positive Mid-Stage Trial Results By Investing.com - Investing.com Nigeria
AtaiBeckley reports positive Phase 2a trial results for EMP-01 - Investing.com
Experimental MDMA pill eases severe social anxiety in early AtaiBeckley trial - Stock Titan
A Look At AtaiBeckley (ATAI) Valuation After Virtual Investor Day Announcement And Strong Recent Returns - simplywall.st
AtaiBeckley’s Contradictory Indicators: Rising Cash Meets Negative Chart Trends - Bitget
JonesTrading Maintains AtaiBeckley(ATAI.US) With Buy Rating, Maintains Target Price $16 - 富途牛牛
AtaiBeckley CFO Change Puts Funding And Dilution In Sharper Focus - simplywall.st
Why AtaiBeckley (ATAI) Is Up 11.2% After CFO Transition And Virtual Investor Day Announcement - Yahoo Finance
Ataibeckley Inc (ATAI) 財務データ
収益
当期純利益
現金流量
EPS
4.32%
大文字化:
|
ボリューム (24 時間):